Growth Opportunities and Trends in the Imfinzi (durvalumab) Market: Key Insights for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the imfinzi (durvalumab) market?
Over the past few years, the market for imfinzi (durvalumab) has seen substantial growth. Anticipated to expand from $2,701.22 million in 2024 to $3,013.33 million in 2025, it boasts a compound annual growth rate (CAGR) of 11.6%. Factors such as increased indications and approvals, the rising demand for targeted and personalized therapies, enhancements in immunotherapy, and an upward trend in patient interest for immunotherapies are all responsible for the growth witnessed in the historic period.
What will be the imfinzi (durvalumab) market size in the future?
Expectations are that the market size for imfinzi (durvalumab) will experience significant growth in the coming years. The forecast suggests that it will increase to $4,143.36 million by 2029, exhibiting a compound annual growth rate (CAGR) of 11.3%. Factors contributing to this anticipated growth during the forecast period include increased use of combined treatments, enhanced pharmaceutical research and development, an escalating occurrence of cancer, a surge in the acceptance of immunotherapy, expanding regulatory influence, and heightened investment in healthcare facilities. Major future trends incorporate the utilization of tailored medicine techniques, emphasis on personalized medicine, adoption of biosimilars, integration of artificial intelligence and machine learning technologies, and partnerships within the pharmaceutical industry.
Get your imfinzi (durvalumab) market report here!
https://www.thebusinessresearchcompany.com/report/imfinzi-durvalumab-global-market-report
What main drivers are fueling expansion in the imfinzi (durvalumab) market?
An increase in cancer occurrences is anticipated to propel the development of the Imfinzi (durvalumab) market in the future. Cancer is a group of diseases marked by the uncontained development and dissemination of unhealthy cells in the human body, capable of invading and obliterating normal tissue. Cancer’s increasing prevalence can be attributed majorly to an aging demographic as the possibility of cancer enhances with age and lifestyle variables such as smoking, improper diet, and obesity that add to heightened cancer rates. The drug durvalumab (Imfinzi) impedes the PD-L1 protein, thereby preventing cancer cells from escaping the immune system’s detection. As an illustration, the National Cancer Institute in May 2024 reported that in 2022 the U.S. had 18.1 million cancer survivors, and this number is projected to reach 22.5 million by 2032. This surge in cancer incidences is aiding the Imfinzi (durvalumab) market’s expansion. An upward trend in personalized medicine is set to further stimulate the growth of the Imfinzi (durvalumab) market. Personalized medicine refers to a medical model that adapts treatment and healthcare plans to the specific attributes of each patient including their gene pattern, surroundings, and lifestyle. The burgeoning precedent of personalized medicine can be attributed to progress in genomic technology, enhanced understanding of molecular biology, the extending availability of diagnostic instruments with precision, and the appeal for targeted therapies that optimize patient outcomes while reducing adverse effects. Imfinzi (durvalumab) bolsters personalized medicine by facilitating custom immunotherapy treatments for cancer sufferers rooted in particular tumor biology and immune system features, consequently augmenting treatment potency and eliminating needless side effects. According to the Personalized Medicine Coalition in 2023, the FDA sanctioned personalized medicine for 34% of emerging drugs in 2022, and in the previous eight years, they had been sanctioned for a minimum of 25% of novel drugs. Hence, the rise of personalized medicine propels the Imfinzi (durvalumab) market.
What key areas define the segmentation of the global imfinzi (durvalumab) market?
The imfinzi (durvalumab)market covered in this report is segmented –
1) By Type: 2.4mL Injection; 10mL Injection
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19906&type=smp
Who are the dominant players expanding their reach in the imfinzi (durvalumab) market?
Major companies operating in the imfinzi (durvalumab) market include AstraZeneca PLC.
How are evolving market trends shaping imfinzi (durvalumab) Strategies?
The primary trend in the imfinzi (durvalumab) market involves efforts to secure regulatory clearances with the aim of extending its use for more cancer forms, broadening its clinical applications, and enlarging its market footprint. These regulatory consents are formal permissions given by governmental health bodies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), which allow a medication, medical device, or treatment to be sold and applied in specific areas. For example, AstraZeneca, a pharmaceutical firm based in the UK, gained FDA clearance for durvalumab (Imfinzi) in September 2022 for treating locally progressed or metastatic biliary tract cancer (BTC) in adults. This was based on the TOPAZ-1 trial results, a landmark study showing that durvalumab, when used with gemcitabine and cisplatin, meaningfully boosted overall survival (12.8 months compared to 11.5 months for placebo) and progression-free survival (7.2 months compared to 5.7 months). The study was comprised of 685 patients with different types of BTC, with commonly reported side effects like fatigue, nausea, and abdominal pain. The suggested dose is 1,500 mg every three weeks during combined treatment, followed by once every four weeks as a standalone therapy.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19906
Which regions are emerging as leaders in the imfinzi (durvalumab) market?
North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Autoimmune Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report
PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025
mRNA Cancer Vaccines And Therapeutics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
